Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and ...

Prostate-specific antigen screening resulted in 13% lower prostate cancer mortality over a median 23 years of follow-up.

The study found that the five-year mortality rate was significantly lower among patients who were using GLP-1 receptor ...

If everyone eligible had a lung cancer screening, 62,000 lives would be saved over five years, a new study shows.

Prostate cancer incidence is increasing, especially in advanced stages, reversing previous declines and slowing mortality rate improvements. Racial disparities persist, with Black and Native American ...

France reports a high cancer incidence but comparatively low mortality, with differences across datasets driven by ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

While drugs like Wegovy, Ozempic and Mounjaro are hailed for regulating blood sugar and helping people lose weight, new ...

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) use was significantly associated with a reduced odds of five-year mortality, but this protective effect was found to be statistically significant ...

In a retrospective analysis, patients with colon cancer taking GLP-1 agonists had a 62% lower risk of 5-year mortality ...

GLP-1 receptors - the drugs behind Ozempic and Mounjaro - could have great benefits for colon cancer patients, the study ...